Brief: Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
03/12/2024 12:40
Dec 3 (Reuters) - Arrowhead Pharmaceuticals Inc
ARWR.O :
* ARROWHEAD PHARMACEUTICALS REQUESTS REGULATORY CLEARANCE TO
INITIATE PHASE 1/2A STUDY OF ARO-ALK7 FOR THE TREATMENT OF
OBESITY
Source text: ID:nBw8khfDNa
Further company coverage: ARWR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers